Ignite Creation Date:
2025-12-24 @ 11:46 AM
Ignite Modification Date:
2026-01-01 @ 10:59 PM
Study NCT ID:
NCT06067061
Status:
TERMINATED
Last Update Posted:
2025-06-11
First Post:
2023-09-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
Sponsor:
Institut Curie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-05
Start Date Type:
ACTUAL
Primary Completion Date:
2025-05-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-05-07
Completion Date Type:
ACTUAL
First Submit Date:
2023-09-25
First Submit QC Date:
None
Study First Post Date:
2023-10-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-06
Last Update Post Date:
2025-06-11
Last Update Post Date Type:
ACTUAL